CN107148473B - β-内酰胺酶制剂及其用途 - Google Patents

β-内酰胺酶制剂及其用途 Download PDF

Info

Publication number
CN107148473B
CN107148473B CN201580059890.6A CN201580059890A CN107148473B CN 107148473 B CN107148473 B CN 107148473B CN 201580059890 A CN201580059890 A CN 201580059890A CN 107148473 B CN107148473 B CN 107148473B
Authority
CN
China
Prior art keywords
beta
lactamase
weight
modified
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580059890.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107148473A (zh
Inventor
A·布里斯托尔
M·卡拉科
S·康奈利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Treva Biologicals Co ltd
Original Assignee
Synthetic Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Biologics Inc filed Critical Synthetic Biologics Inc
Publication of CN107148473A publication Critical patent/CN107148473A/zh
Application granted granted Critical
Publication of CN107148473B publication Critical patent/CN107148473B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201580059890.6A 2014-10-08 2015-10-08 β-内酰胺酶制剂及其用途 Active CN107148473B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462061507P 2014-10-08 2014-10-08
US62/061,507 2014-10-08
US201562126556P 2015-02-28 2015-02-28
US62/126,556 2015-02-28
US201562205443P 2015-08-14 2015-08-14
US62/205,443 2015-08-14
PCT/US2015/054606 WO2016057744A1 (en) 2014-10-08 2015-10-08 Beta-lactamase formulations and uses thereof

Publications (2)

Publication Number Publication Date
CN107148473A CN107148473A (zh) 2017-09-08
CN107148473B true CN107148473B (zh) 2021-08-06

Family

ID=55653744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580059890.6A Active CN107148473B (zh) 2014-10-08 2015-10-08 β-内酰胺酶制剂及其用途

Country Status (10)

Country Link
US (3) US10105322B2 (enExample)
EP (1) EP3204495B1 (enExample)
JP (1) JP6672277B2 (enExample)
KR (1) KR102467968B1 (enExample)
CN (1) CN107148473B (enExample)
AU (1) AU2015330937B2 (enExample)
CA (1) CA2962959C (enExample)
ES (1) ES2806426T3 (enExample)
MX (1) MX2017004473A (enExample)
WO (1) WO2016057744A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106574273B (zh) 2014-08-28 2021-07-02 合成生物制品有限公司 β-内酰胺酶的基于大肠杆菌的生产
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
EP3261662B1 (en) 2015-02-23 2021-07-21 Synthetic Biologics Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
US10709773B2 (en) 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
WO2018005606A1 (en) * 2016-06-28 2018-01-04 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
CN110062623A (zh) * 2016-11-01 2019-07-26 合成生物制品有限公司 用于减弱抗生素抗性的方法和组合物
SG10201609137PA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Gamma-polyglutamic acid and zinc compositions
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
US20200108130A1 (en) * 2017-03-21 2020-04-09 Synthetic Biologics, Inc. Beta-lactamase formulations
KR20200074982A (ko) * 2017-10-25 2020-06-25 다 볼떼라 베타-락타마아제 변이체
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
MX2021001393A (es) * 2018-08-05 2021-04-12 Da Volterra Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
CA3136833A1 (en) * 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease
WO2021183684A1 (en) * 2020-03-10 2021-09-16 AI:ON Innovations, Inc. System and methods for mammalian transfer learning
CN112137984B (zh) * 2020-10-30 2023-02-03 四川制药制剂有限公司 头孢克洛胶囊及其制备工艺
WO2023168316A1 (en) * 2022-03-04 2023-09-07 Michael Ogburn Enteric coated dry powdered cannabinoid formulations
CN116790567B (zh) * 2022-12-30 2026-03-17 扬州大学 来源于土壤宏基因组的β-内酰胺酶及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038341A (zh) * 2010-05-24 2013-04-10 普维阿布公司 经修饰的β-内酰胺酶及其相关方法和应用
WO2013071421A1 (en) * 2011-11-17 2013-05-23 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL89987C (enExample) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
JP2813809B2 (ja) * 1989-06-19 1998-10-22 武田薬品工業株式会社 有核顆粒製剤およびその製造法
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) * 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
DK1078628T3 (da) * 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
JPH08143476A (ja) * 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
WO1997003185A1 (en) 1995-07-07 1997-01-30 Novo Nordisk A/S Production of proteins using bacillus incapable of sporulation
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
ES2237121T3 (es) * 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
FI4533U1 (fi) * 2000-03-14 2000-08-10 Finnzymes Oy Entsyymikoostumus maidon käsittelemiseksi
DK1391502T3 (da) 2001-05-29 2012-05-21 Kao Corp Værtsmikroorganismer
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
EP1564286A1 (en) 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
CN101257892B (zh) 2005-05-18 2013-01-02 达沃尔泰拉公司 吸附剂的结肠递送
US20070207200A1 (en) * 2006-03-06 2007-09-06 Pozen Inc. Dosage forms for administering combinations of drugs
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
FI119678B (fi) * 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
CN102946872A (zh) * 2010-05-03 2013-02-27 阿普塔利斯制药有限公司 包含含有胰酶的消化酶混合物的微丸组合物
US9115079B2 (en) * 2011-07-26 2015-08-25 Meiji Seika Pharma Co., Ltd. NDM inhibitor
CN104080446B (zh) * 2011-11-30 2018-06-29 武田药品工业株式会社 干包衣片
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
BR112016023360B1 (pt) * 2014-04-17 2023-03-07 Synthetic Biologics, Inc Beta-lactamase e seu uso
US9744221B2 (en) * 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US10709773B2 (en) * 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038341A (zh) * 2010-05-24 2013-04-10 普维阿布公司 经修饰的β-内酰胺酶及其相关方法和应用
WO2013071421A1 (en) * 2011-11-17 2013-05-23 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P1A Recombinant β-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin;Ann-Mari Tarkkanen et al;《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》;20090323;第2456页左栏第一段 *

Also Published As

Publication number Publication date
US12178917B2 (en) 2024-12-31
MX2017004473A (es) 2017-10-12
ES2806426T3 (es) 2021-02-17
EP3204495A4 (en) 2018-04-18
AU2015330937B2 (en) 2021-07-15
EP3204495A1 (en) 2017-08-16
CA2962959C (en) 2023-04-04
AU2015330937A1 (en) 2017-05-25
KR20170065649A (ko) 2017-06-13
CA2962959A1 (en) 2016-04-14
US20160101058A1 (en) 2016-04-14
US10105322B2 (en) 2018-10-23
US20210007994A1 (en) 2021-01-14
WO2016057744A1 (en) 2016-04-14
EP3204495B1 (en) 2020-04-22
KR102467968B1 (ko) 2022-11-16
US20180360762A1 (en) 2018-12-20
US10828260B2 (en) 2020-11-10
JP2017535521A (ja) 2017-11-30
JP6672277B2 (ja) 2020-04-01
CN107148473A (zh) 2017-09-08

Similar Documents

Publication Publication Date Title
KR102467968B1 (ko) 베타-락타마제 제형 및 이의 용도
JP7530933B2 (ja) 経口抗生物質からのマイクロバイオーム防御
CN107530406B (zh) 用于保护肠微生物群系的与抗生素一起使用的碳青霉烯酶
US11596674B2 (en) Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
JP2023025091A (ja) 抗生物質耐性を減弱するための方法および組成物
US20200108130A1 (en) Beta-lactamase formulations
HK1241918B (en) Beta-lactamase formulations and uses thereof
HK1241918A1 (en) Beta-lactamase formulations and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Maryland, USA

Patentee after: Treva Biologicals Co.,Ltd.

Address before: Maryland, USA

Patentee before: SYNTHETIC BIOLOGICS, Inc.

CP01 Change in the name or title of a patent holder